Stockscreener 앱 받기
13.61
0.29%
0.04
시장 영업 전:
13.65
0.04
+0.29%
전일 마감가:
$13.57
열려 있는:
$13.46
하루 거래량:
5.64M
Relative Volume:
0.56
시가총액:
$15.85B
수익:
$14.29B
순이익/손실:
$-3.51B
주가수익비율:
-4.5975
EPS:
-2.9603
순현금흐름:
$1.85B
1주 성능:
+1.26%
1개월 성능:
-4.29%
6개월 성능:
+36.24%
1년 성능:
+74.71%
1일 변동 폭
$13.38
$13.64
1주일 범위
$13.12
$13.66
52주 변동 폭
$6.85
$16.47
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
13.61 | 15.80B | 14.29B | -3.51B | 1.85B | -2.9603 |
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.95B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
119.99 | 50.55B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
10.01 | 44.44B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.96 | 35.54B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
574.77 | 25.49B | 3.18B | 1.33B | 1.04B | 27.90 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 업그레이드 | UBS | Neutral → Buy |
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Momentum Shift: Is Viatris Inc impacted by rising ratesWeekly Loss Report & Weekly High Momentum Picks - baoquankhu1.vn
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viagra Maker Blocks Rival's 'Kamagra' TM - Law360
Viatris sets long-term targets ahead of investor event - MSN
How Effexor’s New GAD Approval And MR-139 Setback At Viatris (VTRS) Has Changed Its Investment Story - simplywall.st
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Inc (VIA.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris (VTRS) price target increased by 10.80% to 15.70 - MSN
Viatris (VTRS) Valuation In Focus After MR-139 Phase III Failure And Pipeline Setback - simplywall.st
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris (VTRS) 2026 proxy details $14.3B revenue, board refresh and key votes - Stock Titan
Viatris Inc (VIA.HM) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Viatris Inc. (VTRS) Stock forecasts - Yahoo Finance UK
(VTRS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - Investing.com
Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Named a Great Place To Work in India for the Fifth Consecutive Year - businesswireindia.com
Is Effexor’s First-in-Class GAD Approval in Japan Altering The Investment Case For Viatris (VTRS)? - simplywall.st
VTRS PE Ratio & Valuation, Is VTRS Overvalued - Intellectia AI
ACC26 conference visit sees Viatris stock decline amid persistent negative momentum and oversold levels - tradersunion.com
TeraWulf, Viatris, MGM, Nucor, Best Buy Shake-Up - TipRanks
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - GuruFocus
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Vanguard (VTRS) Amendment No.3: Reports 0% Beneficial Ownership After Realignment - Stock Titan
(VTRS.O) | Stock Price & Latest News - Reuters
Empowering the Front Lines: How the NCD Academy Is Transforming Community Level Care - Viatris
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative MedicinesSlideshow (NASDAQ:VTRS) 2026-03-25 - Seeking Alpha
Viatris Named to 3BL’s 100 Best Corporate Citizens of 2023 Ranking - CSRwire
Viatris Insider Sold Shares Worth $283,539, According to a Recent SEC Filing - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Siemens Healthineers AG (SEMHF), Viatris (VTRS) - The Globe and Mail
Top Viatris Executive Makes Notable Move With Insider Stock Sale - TipRanks
Viatris Inc officer Campbell sells $283k in shares By Investing.com - Investing.com India
Viatris Inc officer Campbell sells $283k in shares - Investing.com
Viatris (VTRS) insider trims stake with 21,350-share open-market sale - Stock Titan
Global cardiovascular leaders convene as Viatris joins ACC26 event in New Orleans - Traders Union
Viatris sees positive top-line phase 3 results for night driving impairment asset - MSN
[144] Viatris Inc SEC Filing - stocktitan.net
Barclays raises Viatris stock price target on pipeline potential By Investing.com - Investing.com Australia
Barclays raises Viatris stock price target on pipeline potential - Investing.com
VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder - contractpharma.com
Barclays Adjusts Viatris Price Target to $17 From $15, Maintains Overweight Rating - marketscreener.com
Viatris Stock: Is VTRS Outperforming the Health Care Sector? - Yahoo Finance
Viatris Says Japan Regulator Approves Effexor for Generalized Anxiety Disorder in Adults - marketscreener.com
Viatris wins Japan approval for Effexor to treat anxiety disorder - Investing.com
Japan clears Effexor as first approved GAD treatment for adults - Stock Titan
Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline - The National Law Review
Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD) - Bitget
How (VTRS) Movements Inform Risk Allocation Models - Stock Traders Daily
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.46%
0.15%
자본화:
|
볼륨(24시간):